Abstract
The objective of this study is to investigate the outcome of children 24 months of age or younger (infants) at the time of allogeneic bone marrow transplantation (BMT) for acute leukemia or myelodysplasia. We analyzed the survival rate, prognostic factors, incidences of late sequelae, and immune reconstitution in 22 infants who underwent allogeneic BMT. The 5-year event-free survival estimate was 45.5% (95% confidence interval (CI), 24.4% to 63.3%). Six patients died of transplant-related complications and six died of disease relapse. Remission status at the time of BMT was the most important prognostic factor (P = 0.005): no patient who received a transplant while their disease was not in remission survived, whereas the 5-year survival estimate for infants who underwent BMT during remission was 56% (95% CI, 31% to 75%). Long-term outcomes in the 10 infant survivors were compared with those of 10 older controls matched for diagnosis, disease status at the time of BMT, calendar year at the time of BMT, and source of stem cells. Immune function 1 year after transplantation and the incidences and spectra of late sequelae were similar for both groups during a median of 3.5 years (range, 1.5 to 7.2 years) of follow-up. Bone Marrow Transplantation (2001) 27, 717–722.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Pui CH, Kane JR, Crist WM . Biology and treatment of infant leukemias Leukemia 1995 9: 762–769
Pui CH, Ribeiro RC, Campana D et al. Prognostic factors in the acute lymphoid and myeloid leukemias of infants Leukemia 1996 10: 952–956
Emminger W, Emminger-Schmidmeier W, Haas OA et al. Treatment of infant leukemia with busulfan, cyclophosphamide +/− etoposide and bone marrow transplantation Bone Marrow Transplant 1992 9: 313–318
von Bueltzingsloewen A, Esperou-Bourdeau H, Souillet G et al. Allogeneic bone marrow transplantation following a busulfan-based conditioning regimen in young children with acute lymphoblastic leukemia: a Cooperative Study of the Societe Française de Greffe de Moelle Bone Marrow Transplant 1995 16: 521–527
Woolfrey AE, Gooley TA, Sievers EL et al. Bone marrow transplantation for children less than 2 years of age with acute myelogenous leukemia or myelodysplastic syndrome Blood 1998 92: 3546–3556
Pirich L, Haut P, Morgan E et al. Total body irradiation, cyclophosphamide, and etoposide with stem cell transplant as treatment for infants with acute lymphocytic leukemia Med Pediatr Oncol 1999 32: 1–6
Biondi A, Cimino G, Pieters R, Pui CH . Biological and therapeutic aspects of infant leukemia Blood 2000 96: 24–33
Felix CA, Lange BJ . Leukemia in infants Oncologist 1999 4: 225–240
Reaman GH, Sposto R, Sensel MG et al. Treatment outcome and prognostic factors for infants with acute lymphoblastic leukemia treated on two consecutive trials of the Children's Cancer Group J Clin Oncol 1999 17: 445–455
McLeod HL, Relling MV, Crom WR et al. Disposition of antineoplastic agents in the very young child Br J Cancer 1992 18: (Suppl.) S23-S29
Leung W, Hudson M, Zhu Y et al. Late effects in survivors of infant leukemia Leukemia 2000 14: 1185–1190
Hongeng S, Krance RA, Bowman LC et al. Outcomes of transplantation with matched-sibling and unrelated-donor bone marrow in children with leukaemia Lancet 1997 350: 767–771
Leung W, Hudson MM, Strickland DK et al. Late effects of treatment in survivors of childhood acute myeloid leukemia J Clin Oncol 2000 18: 3273–3279
Phipps S, Dunavant M, Srivastava DK et al. Cognitive and academic functioning in survivors of pediatric bone marrow transplantation J Clin Oncol 2000 18: 1004–1011
Tanner JM, Davies PS . Clinical longitudinal standards for height and height velocity for North American children J Pediatr 1985 107: 317–329
Kaplan EL, Meier P . Nonparametric estimation from incomplete observations J Am Stat Assoc 1958 53: 457–481
Mantel N . Evaluation of survival data and two new rank order statistics arising in its consideration Cancer Chemother Rep 1966 50: 163–170
Cox DR . Regression models and life-tables JR Stat Soc (B) 1972 34: 187–220
Marco F, Bureo E, Ortega JJ et al. High survival rate in infant acute leukemia treated with early high-dose chemotherapy and stem-cell support J Clin Oncol 2000 18: 3256–3261
Woods WG, Kobrinsky N, Buckley JD et al. Timed-sequential induction therapy improves postremission outcome in acute myeloid leukemia: a report from the Children's Cancer Group Blood 1996 87: 4979–4989
Sanders JE . Stem-cell transplant preparative regimens Pediatr Transplant 1999 3: (Suppl. 1) 23–34
Powles R, Singhal S, Treleaven J et al. Identification of patients who may benefit from prophylactic immunotherapy after bone marrow transplantation for acute myeloid leukemia on the basis of lymphocyte recovery early after transplantation Blood 1998 91: 3481–3486
Matthews DC, Appelbaum FR, Eary JF et al. Phase I study of (131)I-anti-CD45 antibody plus cyclophosphamide and total body irradiation for advanced acute leukemia and myelodysplastic syndrome Blood 1999 94: 1237–1247
Knechtli CJ, Goulden NJ, Hancock JP et al. Minimal residual disease status before allogeneic bone marrow transplantation is an important determinant of successful outcome for children and adolescents with acute lymphoblastic leukemia Blood 1998 92: 4072–4079
Bader P, Stoll K, Huber S et al. Characterization of lineage-specific chimaerism in patients with acute leukaemia and myelodysplastic syndrome after allogeneic stem cell transplantation before and after relapse Br J Haematol 2000 108: 761–768
Robinson N, Sanders JE, Benyunes MC et al. Phase I trial of interleukin-2 after unmodified HLA-matched sibling bone marrow transplantation for children with acute leukemia Blood 1996 87: 1249–1254
Slavin S, Naparstek E, Nagler A et al. Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse after allogeneic bone marrow transplantation Blood 1996 87: 2195–2204
Anderson LD Jr, Savary CA, Mullen CA . Immunization of allogeneic bone marrow transplant recipients with tumor cell vaccines enhances graft-versus-tumor activity without exacerbating graft-versus-host disease Blood 2000 95: 2426–2433
Pui CH, Raimondi SC, Srivastava DK et al. Prognostic factors in infants with acute myeloid leukemia Leukemia 2000 14: 684–687
Sanders JE . Long-term effects of bone marrow transplantation Pediatrician 1991 18: 76–81
Davies SM, Ramsay NKC, Klein JP et al. Comparison of preparative regimens in transplants for children with acute lymphoblastic leukemia J Clin Oncol 2000 18: 340–347
Johnson FL, Rubin CM . Allogeneic marrow transplantation in the treatment of infants with cancer Br J Cancer 1992 66: (Suppl. 18) S76-S79
Wimperis JZ, Brenner MK, Prentice HG et al. Transfer of a functioning humoral immune system in transplantation of T-lymphocyte-depleted bone marrow Lancet 1986 15: 339–343
Wahren B, Gahrton G, Linde A et al. Transfer and persistence of viral antibody-producing cells in bone marrow transplantation J Infect Dis 1984 150: 358–365
Singhal S, Mehta J . Reimmunization after blood or marrow stem cell transplantation Bone Marrow Transplant 1999 23: 637–646
Weinberg K, Parkman R . Age, the thymus, and T lymphocytes New Engl J Med 1995 332: 182–183
Mackall CL, Fleisher TA, Brown MR et al. Age, thymopoiesis, and CD4+ T-lymphocyte regeneration after intensive chemotherapy New Engl J Med 1995 332: 143–149
Weinberg K, Annett G, Kashyap A et al. The effect of thymic function on immunocompetence following bone marrow transplantation Biol Blood Marrow Transplant 1995 1: 18–23
Rooney CM, Wimperis JZ, Brenner MK . Natural killer cell activity following T cell-depleted allogeneic bone marrow transplantation Br J Haematol 1986 62: 413–420
Benner MK, Reittie JE, Grob JP . The contribution of large granular lymphocytes to B cell activation and differentiation after T cell-depleted allogeneic bone marrow transplantation Transplantation 1986 42: 257–261
Acknowledgements
This study is supported in part by grant P30 CA21765 from the National Institutes of Health, by the Assisi Foundation of Memphis; by a Center of Excellence grant from the state of Tennessee; and by the American Lebanese Syrian Associated Charities (ALSAC). We thank Margaret Aymond, Cynthia Walker and Patricia Johnson for data collection; Frances Curran and Carol Nash for data management; and Dr Julia Cay Jones for scientific editing.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Leung, W., Pitts, N., Burnette, K. et al. Allogeneic bone marrow transplantation for infants with acute leukemia or myelodysplastic syndrome. Bone Marrow Transplant 27, 717–722 (2001). https://doi.org/10.1038/sj.bmt.1702998
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1702998
Keywords
This article is cited by
-
Outcome of risk-based therapy for infant acute lymphoblastic leukemia with or without an MLL gene rearrangement, with emphasis on late effects: a final report of two consecutive studies, MLL96 and MLL98, of the Japan Infant Leukemia Study Group
Leukemia (2007)
-
Allogeneic BMT for infantile acute leukemia: what is the optimal conditioning regimen?
Bone Marrow Transplantation (2002)